Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
March 15, 2024Acta Pharmaceutica Sinica BOpen Access

Repurposing disulfiram with CuET nanocrystals: Enhancing anti-pyroptotic effect through NLRP3 inflammasome inhibition for treating inflammatory bowel diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

XXXueming XuYHYuanfeng HanJDJiali Deng

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Xu et al. (2024) studied this question.

synapsesocial.com/papers/68e73cb8b6db6435876b61echttps://doi.org/10.1016/j.apsb.2024.03.003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Repurposing Disulfiram for Cancer Therapy: Mechanistic Insights and Translational Challenges2026
  2. 2FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation2024 · 20 citations
  3. 3Exploring the therapeutic potential of disulfiram in endometriosis: mechanisms targeting inflammation, oxidative stress, pyroptosis, and angiogenesis2026 · 2 citations
  4. 4Localized Sustained Release of Copper Enhances Antitumor Effects of Disulfiram in Head and Neck Cancer2024 · 1 citations
  5. 5Unlocking the therapeutic potential of disulfiram in sepsis: Mechanisms and future directions2025